期刊文献+

干扰素α对恶性造血细胞系主要组织相容性复合体I类链相关蛋白A表达的上调作用 被引量:1

Up-regulation of major histocompatibility complex class I chain-related protein A expression in the malignant hematopoietie cell lines by interferon-a
原文传递
导出
摘要 目的观察干扰素a(IFN-a)对恶性造血细胞系主要组织相容性复合体(MHC)I类链相关蛋白A(MICA)表达的影响。方法反转录-聚合酶链反应(RT-PCR)法检测人类慢性髓系白血病细胞K562及人类伯基特淋巴瘤细胞Raji细胞MICAmRNA的表达,免疫组织化学法检测MICA蛋白的表达,四甲基偶氮唑蓝(MTF)比色法检测人类外周血自然杀伤(NK)细胞对肿瘤细胞的杀伤。结果K562细胞MICA表达阳性,Raji细胞MICA表达阴性。Raji和K562细胞分别在1000U/ml IFN-a诱导24h和48h时MICAmRNA开始表达上调(t=17.016,P〈0.05;t=5.616,P〈0.05)。72hRaji细胞和K562细胞分别在500U/ml和1000U/ml诱导条件下MICAmRNA表达开始上调(t=6.622,P〈0.05;t=9.071,P〈0.05)。IFN—Ot对MICAmRNA表达的上调作用呈一定时间和剂量依赖关系,且蛋白与mRNA表达水平一致。1000U/ml IFN—a诱导72h后,Raji细胞和K562细胞对NK细胞杀伤的敏感性明显上调(t=20.016,P〈0.05;t=7.969,P〈0.05),抗MICA抗体封闭MICA后,NK细胞对Raji细胞杀伤率恢复至诱导前水平(t=0.393,P〉0.05),而K562细胞则低于诱导前水平(t=9.841,P〈0.05)。结论IFN—a上调了恶性造血细胞中MICA基因的转录表达,继而增强了NK细胞对其识别与杀伤。 Objeαive To investigate the effeα of interferon-α (IFN-α) on expression of major histocompatibility complex (MHC) class I chain-related protein A (MICA) in the malignant hematopoietic cell lines. Methods The myeloid leukemia cell lines K562 and B-cell lymphoma cell line Raji were treated with IFN-α. The expression of MICA was measured by RT-PCR and immunohistochemical staining at mRNA and protein level. The cytotoxicity of human NK cells to the IFN-α treated malignant hematopoietic cells was deteαed by MTr method. Results After being treated with 1000 U/ml IFN-α, up-regulation of MICA mRNA in Raji and K562 cells were respeαively found in 24 h and 48 hours (t =17.016, P 〈0.05; t =5.616, P 〈0.05). After being treated with IFN-ot 72 hours, up-regulation of MICA mRNA in K562 and Raji were found at the dose of 500 U/ml and 1000 U/ml dose (t =6.622, P 〈0.05; t =9.071, P 〈0.05). The mRNA and protein expression of MICA were up-regulated by IFN-ot in the two malignant hematopoietic cells in a time and dose- dependent manner. After being treated with 1000 U/ml IFN-α for 72 hours, the susceptibility of the two malignant hematopoietic cells to NK cytolysis was significantly increased (t = 20.016, P 〈0.05; t = 7.969, P 〈0.05). Moreover, the up-regulated susceptibility can be blocked by anti-MICA antibody. Conclusion IFN-ot can up-regulate the MICA expression in the malignant hematopoietic cell lines and thereby enhance the susceptibility to cytolysis of NK cells.
出处 《白血病.淋巴瘤》 CAS 2011年第12期734-737,共4页 Journal of Leukemia & Lymphoma
基金 国家自然科学基金(30371302、90713033) 山东省自然科学基金(Y2002C24)
关键词 干扰素A 基因 MHC I类 杀伤细胞 天然 MICA Interferon-alpha Genes, MHC cell I Killer cells, natural MICA
  • 相关文献

参考文献7

  • 1Allan NC, Shepherd PCA, Richards SM. UK medical research council randomized, muhicentre trial of interferon-alpha nl for chronic myeloid leukemia: improved survival intrespective of cytogenetic response. The UK medical research council's working parties for therapeutic trials in adult leukemia. Lancet. 1995, 345: 1392-1397.
  • 2孙自敏,刘欣,朱薇波,汪健,潘理明,吴树农,吴竞生,蔡晓燕,余自强.干扰素α-2b联合低剂量阿糖胞苷治疗慢性髓细胞白血病的临床研究[J].白血病.淋巴瘤,2004,13(1):23-25. 被引量:3
  • 3洪虹,丘镜滢,赖悦云,师岩,何琦,党辉,陆道培.干扰素-α治疗Ph^+慢性粒细胞白血病的细胞遗传学反应分析[J].中国实验血液学杂志,2003,11(3):269-273. 被引量:2
  • 4牛家峰,张彩,张建华,许晓群,张维东,王郡甫,高春义.IFN-α对宫颈癌细胞MHC-I类链相关蛋白A表达的上调作用[J].细胞与分子免疫学杂志,2006,22(5):557-559. 被引量:3
  • 5Zhang C, Zhang J, Wei H, et al. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity? Int Immunopharmacol, 2005, 5:1099-1111.
  • 6Gonzalez S, Groh V, Spies T. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol, 2006, 298: 121-138.
  • 7Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 2002, 62: 6178-6186.

二级参考文献13

  • 1Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinaerine fluorescence and Giexnsa staining. Nature, 1973; 243:290-293.
  • 2The European Study Group on Interferon in Chronic Myeloid Leukemia. Chronic myelold leukemia and interferon-α: a study of complete cytogenetic responders. Blood, 2001 ; 98:3074 - 3081.
  • 3Mitelman F. ISCN(1995) : An international system for human cytogenetic nomenclature. Basel:Karger, 1995.
  • 4Baccarani M. Rosti Q, de-Vivo A, et al. A randomized study of IFN-α versus IFN-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 2002; 99:1527-1535.
  • 5Hochhaus A, Reiter A, Sanssele S, et al. Molecular heterogeneity in complete cytogenetic responders after interferon a therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Group and the UK MRC CML Study Group. Blood, 2000; 95:62-65.
  • 6Mahon FX, Faberes C, Pueyo S, et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon a. Blood, 1998;92 : 4059 - 4065.
  • 7Anonymous. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-2b for chronic myeloid leukemia. The Benelux CML Study Group. Blood, 1998; 91:2713- 2721.
  • 8Majlis A, Smith T, Talpaz M, et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol,1996; 14 : 196 - 203.
  • 9Johansson B, Fioretos T, BillstrOm R, et al. Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon u. Leukemia, 1996 ; 10 : 1134 - 1138.
  • 10刘映霞,胡国龄,刘敏,何淑雅,谭德明,李红梅.抗NKG2D多克隆抗体抑制NK和LAK细胞细胞毒效应的研究[J].细胞与分子免疫学杂志,2003,19(3):257-259. 被引量:8

共引文献5

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部